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 Abstract 
 Background/Aims: Alzheimer’s disease (AD) is the most common form of dementia. Neuro-
psychological assessment of individuals with AD primarily focuses on tests of cortical func-
tioning. However, in clinical practice, the underlying pathologies of dementia are unknown, 
and a focus on cortical functioning may neglect other domains of cognition, including
subcortical and executive functioning. The current study aimed to improve the diagnostic
discrimination ability of the Consortium to Establish a Registry for Alzheimer’s Disease –
Neuropsychological Assessment Battery (CERAD-NAB) by adding three tests of executive 
functioning and mental speed (Trail Making Tests A and B, S-Words).  Methods: Logistic re-
gression analyses of 594 normal controls (NC), 326 patients with mild AD and 224 patients 
with other types of dementia (OD) were carried out, and the area under the curve values were 
compared to those of CERAD-NAB alone.  Results: All comparisons except AD-OD (65.5%) 
showed excellent classification rates (NC-AD: 92.7%; NC-OD: 89.0%; NC-all patients: 91.0%) 
and a superior diagnostic accuracy of the extended version.  Conclusion: Our findings suggest 
that these three tests provide a sensible addition to the CERAD-NAB and can improve neuro-
psychological diagnosis of dementia.  © 2014 S. Karger AG, Basel 
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 Introduction 
 Neuropsychological assessment plays a crucial role in differential dementia diagnosis 
 [1] . Alzheimer’s disease (AD) is the most common cause of dementia and primarily affects 
‘cortical’ functioning such as verbal episodic memory. Thus, most neuropsychological test 
batteries focus on these cortical cognitive functions  [2] . However, in clinical practice, many 
types of distinct deficits may be observed and multiple hypotheses must be evaluated. Solely 
focusing on cortical functioning may fail to identify other impairments that may be indicative 
of dementia from etiologies other than AD. The goal of the current study was to determine
if the inclusion of tests of subcortical and frontal functioning could improve the diagnos-
tic accuracy of the Consortium to Establish a Registry for Alzheimer’s Disease – Neuropsy-
chological Assessment Battery (CERAD-NAB)  [3] , a commonly used neuropsychological
test battery. Accurate clinical diagnosis of dementia is crucial for determining prognosis
and implementing appropriate disease-specific treatments, also in due consideration of
the enormous healthcare costs caused by dementia  [4] . For diagnostic evaluation, recent 
EFNS-ENS Guidelines recommend that detailed cognitive and neuropsychological assessment 
is performed in all patients  [5] . Much attention has been dedicated toward the development 
of instruments focusing on the detection of the earliest changes in cognitive functions affected 
in dementia  [6, 7] . AD accounts for approximately 70% of all dementia cases and has been 
identified as a research priority  [8] . This focus has led to an increased knowledge about the 
disease and to the identification of deficits in a broad range of cognitive domains. Impairment 
in learning, memory, attention, executive functioning, and language are some of the earliest 
observable cognitive signs of AD (for a review see  [9] ). Although AD is the leading cause of 
dementia in the elderly, dementia can arise from a variety of etiologically and neuropatho-
logically distinct disorders, causing different patterns of cognitive impairment  [2] . Accord-
ing to the actual EFNS-ENS Guidelines, the behavioral variant of frontotemporal dementia 
(FTD) is characterized by a progressive decline in interpersonal skills and emotional disor-
ders such as apathy, emergence of a variety of abnormal behaviors and executive dysfunc-
tions, while in subcortical forms of dementia, such as vascular dementia (VaD), disruption of 
subcortical frontal loops may lead to psychomotor slowing and executive dysfunctions  [5] . In 
practice, clinicians must evaluate multiple possible etiologies when determining the potential 
presence and cause of neuropsychological dysfunction.
 For example, different profiles of neuropsychological impairment can distinguish between 
AD and VaD, another common type of dementia. VaD refers to a cumulative decline in cognitive 
functioning secondary to cerebral infarction, ischemic injury, or hemorrhagic lesions  [2] . The 
effects of cerebrovascular disease on cognition have recently been defined by the term vascular 
cognitive impairment  [10] . The most prominent cognitive deficits observed in vascu-
lar cognitive impairment are executive/subcortical functions including goal formulation, initi-
ation, planning, organization, shifting and psychomotor speed  [11] , sequencing, speed of 
mental processing, performance on unstructured tasks and attention  [12] , semantic memory, 
attentional abilities, visuospatial reasoning, and perceptual skills  [13] . In the clinical setting, it 
is challenging to distinguish between VaD and AD because vascular risk factors and stroke may 
also be observed in individuals with AD. Vascular factors, such as cerebrovascular disease/
strokes, and white matter lesions may trigger and/or modify the progression of AD  [10] . 
Several studies  [12, 14] compared the neuropsychological profiles in patients with subcortical 
VaD and patients with AD. The results revealed that memory impairment was more prominent 
than executive dysfunction in almost two thirds of AD patients, whereas patients with subcor-
tical VaD generally showed greater deficits in executive functions than in verbal episodic 
memory. Thus, inclusion of tests examining subcortical/executive functions seems to be a 
promising strategy for distinguishing between impairment due to AD and VaD. 
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 Similarly, tests targeting frontal functions may be helpful for neuropsychological test 
batteries aiming to distinguish between AD and FTD. FTD, for example, may make up 50%
of dementia cases in adults younger than 60 years of age  [15] and 6–12% of late-onset de-
mentia cases  [16] . Drawing a clinical distinction between FTD and AD can be difficult, partic-
ularly at the early stages of disease  [17] . Previous studies  [18, 19] have observed that patients 
with FTD are typically more impaired than patients with AD on spontaneous word generation 
tasks (i.e., letter and category fluency). In contrast, patients with FTD demonstrate lesser 
deficits on tests of memory and visuospatial abilities compared to patients with AD. Rascov-
sky et al.  [20] were able to distinguish patients with FTD and AD using two verbal fluency 
measures. They observed that patients with FTD exhibit worse performance on letter fluency 
compared to semantic category fluency, whereas patients with AD perform worse on semantic 
category fluency compared to letter fluency. This contrasting pattern of fluency deficits in 
FTD and AD may indicate the differences in the relative contribution of frontal lobe-mediated 
retrieval deficits (more prominent in FTD) and temporal lobe-mediated semantic deficits 
(more prominent in AD) in the two disorders  [2] . Inclusion of both semantic category fluency 
and letter fluency in a neuropsychological test battery might provide additional information 
about the underlying pathology and enhance the validity of dementia diagnosis. 
 In this study, we extend the well-established CERAD-NAB  [3] , German version, with tests 
assessing processing speed (Trail Making Test A, TMTA  [21] ), executive functioning (Trail 
Making Test B, TMTB  [21] ), and frontal functions (letter fluency: S-Words)  [22] to determine 
whether these additions may enhance dementia diagnosis compared to the CERAD-NAB 
alone. The time needed for the administration of these additional tests will increase the 
neuropsychological assessment by approximately 10 min. We compared patients with AD to 
normal controls (NC) and also to other types of dementia, including VaD, FTD, and mixed 
dementia (MD). Our hypothesis is that the extended battery will result in superior discrimi-
nation between AD and NC and also between AD and other types of dementia. We will also 
illustrate the clinical utility of our findings by applying them to two cases and determine their 
probabilities of having dementia.
 Materials and Methods 
 Participants 
 NC Group 
 The sample of cognitively healthy elderly individuals was selected from the BASEL (BAsel 
Study on the ELderly) project  [23] , a longitudinal study that aims to identify preclinical 
markers of AD. This project was approved by our local ethics committee, and written informed 
consent was obtained from all participants. Eleven hundred participants qualified for inclusion 
in the current sample. The following inclusion and exclusion criteria were applied for study 
inclusion: (1) German as first language; (2) no more than one age-, gender-, and education-
corrected Z-score  ≤ –1.96 on any variable on the German version of the CERAD-NAB  [24] ;
(3) absence of systemic or neurological illnesses according to self-reported medical history; 
(4) participants did not meet diagnostic criteria for a current major depressive episode 
according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
 [25] ; (5) participants did not demonstrate any visual or hearing impairment that could have 
adversely influenced the neuropsychological assessment; (6) a minimum age of 50 years; (7) 
at least 7 years of formal education, and (8) a Mini-Mental State Examination (MMSE) score 
 [26]  of  ≥ 24. Out of these 1,100 individuals, 594 participants completed TMTA, TMTB and 
S-Words and composed the NC sample for the current study. Demographic characteristics are 
displayed in  table 1 .
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 AD Patients with Very Mild to Mild Dementia 
 Patients were chosen from the Memory Clinic, University Hospital, Basel, Switzerland, 
where they had been diagnosed with probable AD according to the criteria of the National 
Institute for Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA)  [27]  and of the DSM-IV  [25] . 
The multidisciplinary assessment included (1) independent, detailed clinical interviews with 
the patient and (where possible) informant formally assessing patients’ mood and cognitive 
and everyday functioning; (2) thorough medical examinations including neurological status; 
(3) an MRI examination with sequences optimized to detect structural brain abnormalities 
associated with cognitive impairment; (4) a complete laboratory workup, and (5) a compre-
hensive neuropsychological testing including the German version of the CERAD-NAB plus 
TMTA and S-Words. Diagnoses were established at an interdisciplinary diagnosis confer-
ence with geriatricians, neurologists, neuropsychologists, a neuropathologist, neuroimaging 
experts, and psychiatrists (for details of these assessments and procedures, see  [28] ). Since 
CERAD-NAB data were available at the diagnosis conference, the question of circularity aris-
es, i.e. the concern that the reported correct classification rate (CCR) of the CERAD-NAB was 
artificially inflated because patients may have been a priori defined as individuals with lower 
CERAD-NAB scores. However, diagnoses were never based on the neuropsychological 
assessment alone, but rather on the integration of all comprehensive multidisciplinary 
findings, which cannot logically be equated with a particular CERAD-NAB score. Nevertheless, 
we cannot completely rule out that the reported CCR was artificially inflated by the avail-
ability of CERAD-NAB scores at the diagnosis conference. The group comprised 326 patients 
with AD. Demographic characteristics are shown in  table 1 . All participants scored at 24 or 
higher on the MMSE, ensuring that participants were in a very early stage of the disease  [24] . 
 Patients with Other Types of Dementia 
 In order to gain a sample with types of dementia other than AD (OD), we included 224 
individuals who obtained a diagnosis of a dementia with a subcortical component at the 
Memory Clinic Basel. Diagnosis was established as noted above. Characteristics of the study 
sample are displayed in  table 1 . Three subgroups were defined within the OD group.
 One hundred and sixteen individuals received a diagnosis of MD. These patients received 
a diagnosis of probable AD according to NINCDS-ADRDA and DSM-IV criteria and also met 
criteria for a subcortical component of dementia according to Erkinjuntti et al.  [11] . The diag-
nosis of MD necessarily includes a cognitive syndrome (both memory impairment and dysex-
ecutive syndrome) with evidence of a relevant cerebrovascular disease by brain imaging and 
presence or history of neurologic signs as evidence for cerebrovascular disease.
 Table 1.  Characteristics of the study sample
Groups NC AD OD  OD subgroups
MD VaD FTD
Participants 594 326 224 116 69 39
Sex, male/female 331/263 137/189 123/101 63/53 36/33 24/15
Age, years 68.37 ± 7.66 75.66 ± 5.91 75.17 ± 7.46 77.34 ± 5.71 75.07 ± 6.97 68.87 ± 9.29
Education, years 12.32 ± 3.00 11.83 ± 3.05 12.31 ± 3.18 12.44 ± 3.30 12.06 ± 3.06 12.36 ± 3.10
MMSE score [24] 28.9 ± 1.14 26.2 ± 1.60 26.5 ± 1.60 26.3 ± 1.58 26.7 ± 1.53 26.6 ± 1.58
 Values are numbers or mean ± SD.
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 Ninety-six patients were diagnosed with probable VaD according to criteria set forth by 
Roman et al.  [29] . These criteria included (1) dementia (decline in memory and deficits in at 
least one additional domain), and (2) existence of a cerebrovascular disease (focal neuro-
logical signs consistent with stroke) with supportive evidence from a computed tomography 
or MRI scan.
 Thirty-nine patients were diagnosed with FTD using criteria set forth by Neary et al.
 [30] . Core diagnostic features essentially included (1) insidious onset and gradual progression; 
(2) early decline in social and interpersonal conduct in the course of the disease; (3) ear-
ly impairment in regulation of personal conduct; (4) early emotional blunting, and (5) early 
loss of insight. 
 Cognitive Tests 
 We used Z-scores adjusted for age, gender, and education  [31, 32] for all measures.
 CERAD-NAB 
 The German version of the CERAD-NAB consists of nine different tasks measuring 
cognitive performance in domains including memory, language, praxis, and orientation. The 
current study added three additional tests examining frontal, subcortical, and executive func-
tioning to the CERAD-NAB. We will henceforth refer to this expanded test battery as CERAD-
NAB Plus, consisting of 12 variables. 
 Frontal executive functions were measured using S-Words, a task measuring the ability 
of participants to generate as many words as possible beginning with the given letter ‘S’ 
within 60 s. In this measure, the following restrictions are given to participants: any words 
are allowed except for proper nouns, numbers, composite words, or words that are the same 
as a previously used word with a different tense or suffix. Performance is evaluated with the 
total number of words listed.
 Subcortical functioning was evaluated using TMTA, a measure of psychomotor speed and 
visual scanning. In this measure, participants must draw lines connecting the numbers 1 
through 25 in ascending order as quickly as possible. The numbers are distributed over
a sheet of paper. Performance is evaluated using the total completion time. A maximum of
180 s is allowed. Errors are not included in evaluating scores; however, all errors are correct-
ed, which may increase the completion time for the task.
 Executive functioning was evaluated using TMTB, a measure of mental flexibility and the 
ability to switch between two different modalities. In TMTB, both numbers (1–13) and letters 
(A–L) are distributed over a sheet of paper. Participants are asked to draw lines to connect 
numbers and letters in ascending pattern, but with the added task of alternating between 
modalities (i.e., 1-A-2-B-3-C, etc.). Again, performance is evaluated using the total completion 
time in seconds. A maximum of 300 s is allowed. 
 Missing Values in the TMT 
 The sample contained missing values in the TMT. The reasons for missing values included 
premature interruption of the test by the participant or examiner, inadequate comprehension 
of test instructions, and excess of the maximal time allowed. Detailed information about 
distribution of missing data can be found in  table 2 .
 TMTB data were missing for 51.9% of the AD sample and 44.6% of the OD patients. 
Considering this large amount of missing data, we searched for an appropriate method to 
replace the values. Since the values were missing due to censoring (see above), neither 
replacement by a mean value nor replacement by the lowest value of 300 s is acceptable; both 
methods would result in a strong bias. Instead, we estimated a penalty that can be applied to 
the individual Z-scores of the noncompleters at the lowest value of 300 s. In order to create 
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such a penalty, we focused on those subjects who completed the TMTB in the time interval 
between 240 and 300 s (needing at least 80% of the maximum time allowed) and those 
subjects who did not complete the TMTB. We aimed to compare their respective sample 
means to a representative score for test performance. We chose the z-values of the CERAD 
total score  [24] . The slowest 20% of the sample of completers showed a mean of –2.41, while 
the noncompleters achieved a mean of –3.24. The resulting difference of 0.83 is a possible 
penalty that could be derived from the Z-score equal to the worst performance in the TMTB 
in each participant who failed in this test. The same procedure has been applied for the 
interval between 270 and 300 s (the slowest 10% of the sample of completers, mean = –2.54), 
with a possible penalty of 0.6. We decided to subtract a ‘penalty’ of 0.7 from the patient’s 
Z-score for TMTB of 300 s. This procedure ensures an individual, demographically adjusted 
penalty for individuals who could not complete the task. The same procedure was carried out 
for missing values on TMTA, resulting in a penalty of 0.4.
 Statistical Analysis 
 The first aim of the study was to get information about the ability of CERAD-NAB alone 
and CERAD-NAB Plus to correctly differentiate between patients with different kinds of 
dementia and NC. A comparison of their discrimination abilities was performed. The follow-
ing groups were compared using respective cutoff values (share of patients in the entire sam-
ple): (1) NC versus AD to gain information about the difference of correct classification in NC 
and cortical dementia; (2) NC versus OD to examine classification between NC and frontal/
subcortical dementia and NC; (3) NC versus all dementias (DEM) to provide information 
about correct classification of NC and all types of dementia, and (4) AD versus OD to show the 
contribution of the ‘plus’ tests (TMTA, TMTB, and S-Words) in differentiating between cortical 
and subcortical/frontal dementia. Logistic regression analyses were performed on all 9 or 12 
CERAD-NAB or CERAD-NAB Plus scores, respectively. This method assigns an optimal weight 
to each variable in the model in order to achieve the best CCRs and corresponding sensitiv-
ities and specificities. However, due to intercorrelations in the predictors, some regression 
coefficients were assigned coefficients with an algebraic sign inconsistent with the direction 
predicted by theory (i.e., a higher Z-score predicted a higher probability of dementia). 
Therefore, a penalization method was applied. In clinical practice usually all tests from the 
CERAD-NAB are carried out. In order to gain information about the influence of every single 
variable, we chose the penalization by ridge regression. By doing so, all regression coeffi-
cients are reduced but remain in the model. The optimal penalization parameter lambda was 
estimated by cross-validation, using the R package glmnet. The obtained coefficients are more 
stable and were applied to the dataset, resulting in a prediction score for each group 
comparison. Based on the receiver operating characteristic (ROC), optimal CCR and the corre-
sponding sensitivity and specificity were determined for each model. The discrimination abil-
ities of the two test batteries were compared using the area under the curve (AUC) method 
according to DeLong et al.  [33] , as implemented in the R package pROC  [34] .
 A concern of this study was to illustrate the implementation of our findings in clinical 
practice by applying them to randomly selected patients and computing their probability of 
Groups Missing values 
in TMTA [19]
Missing values 
in TMTB [19]
NC (n = 594) 0 7 (1.1%)
AD (n = 326) 13 (4.0%) 169 (51.8%)
OD (n = 224) 6 (1.8%) 100 (44.6%)
 Table 2. Number and 
percentages of missing values in 
the TMTs
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having dementia. Regression weights from the ridge regression models distinguishing 
between NC and demented patients were applied to a randomly chosen patient from the 
Memory Clinic Basel diagnosed with Alzheimer’s dementia ( fig. 1 a) and to a demographically 
comparable healthy individual outside the study sample ( fig. 1 b). Then, we estimated their 
probability of being demented by applying the logistic function to the prediction. A high score 
corresponds to a high probability of being demented. The probability cutoff for distinguishing 
between the two groups was chosen as the proportion of the sample size. 
 Results 
 Optimal weights for each variable gained from ridge regression to distinguish best 
between groups are displayed in  table 3 . The applied coefficients from ridge regression 
( table 3 ) resulted in a prediction score for each group comparison. By producing ROC of this 
score, the optimal CCR and corresponding sensitivity and specificity were conducted. The 
AUC is presented as well for each model. Results are shown in  table 4 . 
 Both CERAD-NAB and CERAD-NAB Plus show an excellent ability to distinguish correctly 
between NC and patients suffering from AD. A correct discrimination of >90% could be 
obtained when diagnosing NC and all demented patients with both batteries. CCR of NC and 
other types of dementia is in general slightly lower than in the antecedent comparisons for 
both batteries but still satisfying (87.55 vs. 88.95%). Comparison of AD versus OD revealed 
no relevant contribution to a satisfactory classification (48.2%) of groups in both CERAD-
NAB and CERAD-NAB Plus.
0
–1.64–2.33 –1.28 –0.67 0.67 1.28
Cognitive profile of a female patient,
73 years old, 10 years of education,
MMSE = 26, diagnosed with AD
0
–1.64–2.33 –1.28 –0.67 0.67 1.28
Cognitive profile of a female patient,
68 years old, 11 years of education,
MMSE = 26, diagnosed with a normal
cognitive status
S-Words [22]
Trail Making Test B [21]
Trail Making Test A [21]
Wordlist savings
Intrusions
Wordlist recall
Constructional praxis [38]
Wordlist encoding [37]
Boston Naming Test [36]
Verbal fluency [35]
Z-scores
Constructional praxis recall
Wordlist recognition
a b
 Fig. 1. CERAD-NAB Plus data from patients examined in the Memory Clinic Basel. 
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Groups CERAD-NAB CERAD-NAB Plus
NC-AD (cutoff: 0.35) λ = 0.56 λ = 0.07
Verbal fluency (animal naming)
Boston Naming Test (15 items)
Wordlist encoding
Constructional praxis
Wordlist recall
Wordlist recognition 
Constructional praxis recall
Intrusions
Wordlist savings
TMTA
TMTB
S-Words
–0.46
–0.22
–0.48
–0.06
–0.45
–0.27
–0.35
–0.21
–0.14
–0.34
–0.15
–0.37
0.03
–0.37
–0.24
–0.28
–0.16
–0.14
–0.16
–0.38
–0.06
NC-OD (cutoff: 0.27) λ = 0.10 λ = 0.07
Verbal fluency (animal naming)
Boston Naming Test (15 items)
Wordlist encoding
Constructional praxis
Wordlist recall
Wordlist recognition 
Constructional praxis recall
Intrusions
Wordlist savings
TMTA
TMTB
S-Words
–0.49
–0.18
–0.37
0.09
–0.33
–0.08
–0.31
–0.16
–0.08
–0.44
–0.14
–0.33
0.04
–0.33
–0.05
–0.26
–0.14
–0.07
–0.21
–0.41
–0.07
NC-DEM (cutoff: 0.48) λ = 0.0.05 λ = 0.06
Verbal fluency (animal naming)
Boston Naming Test (15 items)
Wordlist encoding
Constructional praxis
Wordlist recall
Wordlist recognition
Constructional praxis recall
Intrusions
Wordlist savings
TMTA
TMTB
S-Words
–0.56
–0.20
–0.44
–0.08
–0.41
–0.18
–0.37
–0.22
–0.10
–0.43
–0.14
–0.36
0.03
–0.36
–0.16
–0.30
–0.17
–0.10
–0.18
–0.43
–0.05
AD-OD (cutoff: 0.59) λ = 0.44 λ = 0.40
Verbal fluency (animal naming)
Boston Naming Test (15 items)
Wordlist encoding
Constructional praxis
Wordlist recall
Wordlist recognition
Constructional praxis recall
Intrusions
Wordlist savings
TMTA
TMTB
S-Words
0.10
–0.01
–0.10
0.02
–0.11
–0.12
–0.06
–0.04
–0.04
0.10
–0.01
–0.11
0.03
–0.11
–0.12
–0.07
–0.04
–0.04
0.04
–0.01
0.07
Cutoff values (share of patients in the entire sample) are provided.
 Table 3. Coefficients obtained 
from ridge regression for each 
variable of CERAD-NAB and 
CERAD-NAB Plus that 
differentiate best between the 
observed groups
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 We compared the AUC values between the two batteries using procedures set forth by 
DeLong et al.  [33] to determine whether the CERAD-NAB Plus was significantly better at 
discriminating between the groups than the CERAD-NAB alone. The results revealed that 
CERAD-NAB Plus discriminates significantly better than CERAD-NAB alone between NC
and AD (Z = –2.34, p = 0.0194), NC and OD (Z  = –3.12, p = 0.0018), and NC and DEM (Z  = –3.55, 
p = 0.0004). CERAD-NAB Plus did not distinguish AD from OD significantly better than
CERAD-NAB alone (Z = –1.18, p = 0.2398). 
 In order to illustrate the practical application of the extended test battery, we applied the 
weights obtained from the group comparison between NC and demented patients to the 
CERAD-NAB Plus scores of a randomly selected patient diagnosed with AD in the Memory 
Clinic Basel ( fig. 1 a). First, we replaced the missing value of TMTB by her Z-score for TMTB of 
300 s. We deducted a penalty of 0.7, resulting in a Z-score of –2.84. Applied to the model, a 
prediction score of 2.57 resulted and revealed a probability of 92.89% of being demented. 
The same procedure has been applied to a woman diagnosed as cognitively healthy in the 
Memory Clinic Basel ( fig. 1 b) with similar characteristics; the outcome was a prediction score 
of –1.10 and a probability of 24.97% of being in the demented group. 
 Discussion 
 In addition to domains tested in the well-established CEARD-NAB, the newly created 
CERAD-NAB Plus especially assesses psychomotor speed, executive and frontal functions 
known to be affected particularly in subcortical/frontal forms of dementia. The present study 
provides evidence for an improved correct classification of patients suffering from any type 
of dementia and NC in the CERAD-NAB Plus compared to CERAD-NAB alone. No significant 
differentiation between cortical and subcortical/frontal forms of dementia could be shown in 
both CERAD-NAB and CERAD-NAB Plus.
Statistical values CERAD-NAB, % CERAD-NAB Plus, %
NC-AD (cutoff: 0.35)
Sensitivity
Specificity
CCR
AUC
95.1
90.1
92.6
0.974
92.6
92.8
92.7
0.978
NC-OD (cutoff: 0.27)
Sensitivity
Specificity
CCR
AUC
87.9
87.2
87.6
0.941
92.0
85.9
89.0
0.953
NC-DEM (cutoff: 0.48)
Sensitivity
Specificity
CCR
AUC
90.4
90.2
90.3
0.960
88.9
93.1
91.0
0.967
AD-OD (cutoff: 0.59)
Sensitivity
Specificity
CCR
AUC
84.0
48.2
66.1
0.706
83.1
47.8
65.6
0.712
 Table 4. Sensitivity, specificity, 
CCR and AUC of the CERAD-NAB 
and CERAD-NAB Plus for 
observed group comparisons
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 As a main finding, the current study emphasizes the addition of selected tests to the 
CERAD-NAB in order to improve dementia diagnosis. These tests do not enhance the differ-
ential diagnosis of dementia. Verbal fluency (animal naming) and TMTB appeared to be the 
most valuable variables in all comparisons except AD versus OD. Impaired verbal fluency was 
already described in many influential longitudinal studies searching for preclinical markers 
of dementia 4 (Bronx Aging Study  [39] ), 5 (Canadian Study of Health and Aging  [40] ), 9 
(Personnes Agées QUID  [41] ) and even 12 years (PAQUID  [42] ) before the onset of observable 
clinical symptoms. Impairment on TMTB appeared likewise amongst the earliest preclinical 
signs either in combination with impaired verbal fluency such as in the Baltimore Longitu-
dinal Study of Aging  [43] and in the Cardiovascular Health Study  [44] or isolated in the 
Monogahela Valley Independent Elders Survey  [45] . Two meta-analyses  [40, 46] have stated 
that impairments in frontal nonmemory functions have a predictive value for the conversion 
from mild cognitive impairment (MCI) to AD. Howieson et al.  [47] identified TMTB as one of 
the most significant predictors for conversion from MCI to AD. In a recent study, executive 
functions such as measured by TMTB showed predictive accuracy comparable to that of MRI 
and cerebrospinal fluid biomarkers for the development of AD in amnestic MCI  [48] . In types 
of dementia other than AD, impairment in TMTB, psychomotor speed and verbal fluency even 
dominate the clinical profile of patients, for example, in VaD and MD  [49] as well as in patients 
with vascular white matter lesions. Impaired verbal fluency  [19, 50] and reduced speed of 
processing on the TMT  [51] may be caused by subcortical or frontal lesions, the same func-
tions are known to be affected in patients with small vessel disease, which is related to 
progressive cognitive impairment and a considerable risk of developing dementia  [52] .
 Our findings revealed that the inclusion of executive and frontal function tests as well as 
the survey of psychomotor speed in neuropsychological test batteries is worthwhile to 
improve diagnostic accuracy significantly. This finding is based on a large, reliably diagnosed 
sample, which is a strength of the present study; an MMSE of  ≥ 24 in the patient sample 
ensures an early stage of the disease, and the use of Z-scores, comparable age and education 
within subjects provides a reliable sample that allows a high percentage of correct classifi-
cation. 
 We also demonstrated a method for substituting missing values, which is a common issue 
in clinical research. Missing data are frequent in AD trials due to the age of participants and 
the nature of the disease. This problem can lead to bias and decreased statistical power. 
Analyses of the diagnostic patterns at 30 Alzheimer’s Disease Centers in the United States 
 [53] aimed to identify the most important variables for diagnosis in more than 8,000 patients. 
Missing values of TMTB were observed for a large number of subjects and resulted in exclusion 
of the test from the model in order to include as many cases as possible. Interestingly, when 
using the multiple imputation approach, TMTB was amongst the important predictors of 
diagnosed AD in that study. This finding encourages an appropriate handling of missing 
values. Coley et al.  [54] compared current methods and attested that the Complete Case 
Method as well as the Last-Observation-Carried-Forward (LOCF) method were unsuitable. 
Multiple imputation, longitudinal mixed effects models and Z-score LOCF were declared to be 
more appropriate, but a careful consideration of the validity of the underlying hypotheses of 
methods used was advised for handling missing values. In the present study, we were 
confronted with a large number of missing values in the TMTB in the group of demented 
patients (51.8% AD and 44.6% OD). In contrast, only 1.1% of NC did not complete the test. 
This fact alone already confirms the relevance of TMTB, and therefore, an appropriate 
handling of missing values is crucial. We abstained from multiple imputations since this 
procedure creates multiple random results for a missing value, and we targeted instead a 
distinct value for every individual. Hence, we chose the procedure of deducting a penalty from 
the individual Z-scores of the noncompleters at the lowest possible value in order to ensure 
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an individual, demographically adjusted penalty for noncompliance. This method allows 
clinical application and shows a high prediction ability. 
 There are several limitations of the current study that merit further discussion. First, a 
lack of a gold standard in diagnosing the study sample can be mentioned, and definitive diag-
noses are possible only by histopathology or autopsy. Since histopathology is rarely available, 
clinical diagnosis in accordance with MRI, full blood and serum analysis was used as a 
surrogate gold standard. Another caveat is the selection bias. A homogeneous sample like 
ours might be characterized by a smaller standard deviation of the predictor variable than in 
heterogeneous samples, higher sensitivity and specificity resulting in a facilitated differenti-
ation of patient and control group. Additionally, the setting (Memory Clinic Basel) where the 
patient is examined and diagnosed is a highly specialized unit at a university hospital setting. 
This setting might limit the generalization of the findings to the general population in terms 
of background characteristics because patients at a university hospital are a priori selected 
by means of the referral procedure. Further, the diagnostic accuracy of both CERAD-NAB and 
CERAD-NAB Plus may be partially overestimated: the neuropsychological data used to 
diagnose patients were available to clinicians during the diagnostic process. When using the 
same dataset for selection and selective analysis, there may be a risk of circularity, which 
could confound the estimate of sensitivity and specificity and inflate the CCR. This partial 
circularity may have artificially heightened the diagnostic accuracy .  As mentioned in the 
methods section, we acknowledge this potential flaw and believe to have minimized its extent 
through following arrangements. Assessment included not only neuropsychological exami-
nation but also a variety of specific branches (neurology, psychiatry, imaging techniques and 
laboratory), all of them equally engaged in establishing diagnosis. The impact of CERAD-NAB 
Plus variables was beyond that controlled by presentation of the neuropsychological data 
categorized by domains: none of the obtained cognitive domains was solely represented by a 
single CERAD-NAB-score.
 The CERAD-NAB Plus did not significantly enhance the differential diagnosis of dementia 
in our study. Possible explanations for this poor discrimination might be found in the nature 
of information observed in this study, namely neuropsychological tests. In types of dementia 
other than AD, behavioral changes might be the earliest observable indicators of disease and 
an alternative assessment might be the method of choice in a sample like ours, consisting of 
patients in a very early stage of disease. For example, in FTD, inappropriate social conduct, 
apathy, disinhibition, perseverative behavior, loss of insight, hyperorality, and decreased 
speech output  [55] are more easily observable than neuropsychological deficits at the onset 
of the disease  [30] . An assessment of personality and behavioral changes might be a more 
promising strategy than a comparison of neuropsychological measures alone when distin-
guishing between patients with early-stage FTD and patients with AD. Similarly, VaD might 
be more reliably distinguished from AD by neuroimaging instruments rather than neuropsy-
chological tests alone. For future research, we therefore recommend the extension of neuro-
psychological test batteries with measures such as questionnaires about personality and 
behavioral changes as well as mood changes to determine diagnostic algorithms that combine, 
amongst others, neuropsychological tests, imaging as well as cerebrospinal fluid analyses for 
better diagnosis. 
 In summary, our findings document both CERAD-NAB and CERAD-NAB Plus to be reliable 
measures when differentiating healthy individuals from patients suffering from any kind of 
dementia, whereas none of the two batteries seem to be the method of choice when trying to 
distinguish between early stages of cortical and subcortical or frontal accentuated forms of 
dementia. We support the notion that it is worthwhile to extend the basic CERAD-NAB by 
those three tests, all of them quickly to administer, in order to more reliably classify demented 
patients in clinical practice without overstraining patients.
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